Mycrodose Therapeutics is a US-Based pharmaceutical company specializing in the development of Advanced Drug Delivery (ADD) systems for psychedelic compounds. &nbsp;In this episode of The Integration Conversation, Mycrodose's Chad Conner and Patrick Eckstrom join Brom to discuss how ADD systems can potentially improve the patient experience, increase the safety profile and lower the cost of psychedelic drugs. &nbsp;&nbsp;&nbsp;
 
💰 Invest in Brom's Psychedelic VC Fund:&nbsp;
<a href="https://www.youtube.com/redirect?event=video_description&amp;redir_token=QUFFLUhqa0FDeEVieXprY29rcjlsekVtUXNoSzlhWEloUXxBQ3Jtc0ttS05TV2ltOHF6amhzenM2RjhONnpKd1hxZC1wZTZmVkswY2ZUaDRCSjVqeVB4eHdEdkRmSXIwYjd6a3dkelRJRVlCZ00xd3lVMjFGZ3B3UlI0VFZiRjNsX1ZhUVBoMkdMWW1nUXcyR3JoQUxkMlVyOA&amp;q=https%3A%2F%2Fwww.empath.vc" rel="nofollow" target="_blank">https://www.empath.vc</a> &nbsp;
 
📺 Watch on YouTube:
https://youtu.be/HmBsrUQYyOg&nbsp;
 
🐦 brom on twitter: &nbsp;
<a href="https://www.youtube.com/redirect?event=video_description&amp;redir_token=QUFFLUhqbUdNc3dlc2xiUzRGQXVYU0E2T0otenBrbmFpd3xBQ3Jtc0tuTXk1RUMwSHhxdlc4MG5YVTZfYXdCU2ItMDhCUHcyMF9Gd2M5OUd5R0h4ZllGeHM4SUZhQWRYYnFWRFQ0aDJtamM4WnpVQTBWUnh6MTRiZ1lyb1cyZHlyWXlmaENkc1NNelFuNVFQVmY4anRON2FMQQ&amp;q=https%3A%2F%2Ftwitter.com%2Ftherealbrom" rel="nofollow" target="_blank">https://twitter.com/therealbrom</a>&nbsp;
 
🎇 Clips and other stuff on Instagram: &nbsp;
<a href="https://www.youtube.com/redirect?event=video_description&amp;redir_token=QUFFLUhqbFA3dVROQjVYTTN0dVZJRWNHbVFJWk9pMERZUXxBQ3Jtc0tuS3c1dVpWRC1Kd25lU0FBZUMtaVNpQlBLR3RaS2VaRlJJejQwSkw3dGxla2xnTmJLRTJnekhQTDNBUk5vZ3FSMWFGMDIwc3ZvUExCYlVYT3VWb05EcTVGY2ZFV0dmWXpvc0VIQkswZ1QwMjVDcmVBZw&amp;q=https%3A%2F%2Finstagram.com%2Ftheintegrationco" rel="nofollow" target="_blank">https://instagram.com/theintegrationco</a>&nbsp;
 
💌 Email: &nbsp;&nbsp;
hello@empath.vc

24: 10 Psychedelic Startup Ideas | Request for Psychedelic Startups

The Integration Conversation covers the emerging psychedelic industry. Watch as Hedge Fund veteran and psychedelic enthusiast Brom interviews psychedelic CEOs, performs in-depth analysis of psychedelic companies, and discusses the implications of psychedelics on our society. 

Prior to starting the Integration Conversation, Brom spent 7 years as a quant at multiple hedge funds.  Brom is a CFA charterholder and holds an MS in CS with a focus on Machine Learning from Georgia Tech.  In addition to running the Integration Conversation, Brom is focused on angel investing in psychedelic startups.